HRs and 95% CIs of the association of race and ethnicity with PFS and OS
Race and ethnicity . | PFS . | OS∗ . | ||||
|---|---|---|---|---|---|---|
| . | Model 1† . | Model 2‡ . | . | Model 1† . | Model 2§ . | |
| n (n event) . | HR (95% CI) . | HR (95% CI) . | n (n event) . | HR (95% CI) . | HR (95% CI) . | |
| Non-Hispanic White | 129 (81) | 1.00 (referent) | 1.00 (referent) | 129 (46) | 1.00 (referent) | 1.00 (referent) |
| Hispanic | 16 (11) | 1.45 (0.77-2.73) | 1.10 (0.53-2.30) | 16 (6) | 1.37 (0.58-3.23) | 1.39 (0.54-3.63) |
| Non-Hispanic Black | 29 (19) | 1.33 (0.81-2.21) | 1.22 (0.72-2.08) | 28 (10) | 1.10 (0.55-2.17) | 1.13 (0.54-2.38) |
Race and ethnicity . | PFS . | OS∗ . | ||||
|---|---|---|---|---|---|---|
| . | Model 1† . | Model 2‡ . | . | Model 1† . | Model 2§ . | |
| n (n event) . | HR (95% CI) . | HR (95% CI) . | n (n event) . | HR (95% CI) . | HR (95% CI) . | |
| Non-Hispanic White | 129 (81) | 1.00 (referent) | 1.00 (referent) | 129 (46) | 1.00 (referent) | 1.00 (referent) |
| Hispanic | 16 (11) | 1.45 (0.77-2.73) | 1.10 (0.53-2.30) | 16 (6) | 1.37 (0.58-3.23) | 1.39 (0.54-3.63) |
| Non-Hispanic Black | 29 (19) | 1.33 (0.81-2.21) | 1.22 (0.72-2.08) | 28 (10) | 1.10 (0.55-2.17) | 1.13 (0.54-2.38) |
N = 174.
BCMA, B-cell maturation antigen; ECOG, Eastern Cooperative Oncology Group.
One patient had missing date of death and excluded from models of OS.
Model 1 is unadjusted.
Model 2 includes prior BCMA therapy, high-risk cytogenetics, extramedullary disease, cell dose, ECOG at lymphodepletion chemotherapy, penta-refractory status, age, number of prior lines of therapy, sex, baseline ferritin, and baseline CRP.
Model 2 includes prior BCMA therapy, extramedullary disease, cell dose, ECOG at lymphodepletion chemotherapy, penta-refractory status, age, number of prior lines of therapy, and baseline ferritin. High-risk cytogenetics is included as a strata term.